management
RU-32
You're the CEO of a global pharmaceutical company. After decades of work (and the investment of hundreds of millions of dollars), your scientists have come up with a major breakthrough. Your new drug, RU-32, is a low-cost anti-diabetic medication that dramatically stabilizes insulin levels. If approved, your company will own the patent on a drug worth billions of dollars. However, during Phase III clinical trials, unexpected complications arose, and approval by the FDA is now unlikely. Without FDA approval, you cannot sell RU-32 in the U.S. and most first-world countries. However, other countries––primarily in the third-world––will allow you to market the drug without U.S. FDA approval. You must choose whether to stop all development and cancel the program, or proceed with manufacturing for sale to citizens of third-world countries.
Inform the Board of Directors of your decision. Write a memo explaining your position and your reasons. Be specific and use detailed examples to support your main points.
Over 400 words, please know this is a memo, not like a essay, and have 3 to 4 days to finish it. thank you.
9 years ago
3
Purchase the answer to view it

- memo_solution.docx
- IS Audit Report-
- Assignment
- A chemical reaction
- The Y-E Diagram
- 260 Why
- When finding the quotient of 8397÷12 Calia first divided 83 x 12 as shown below what does a six represent
- Due in 10 hours! five easy reflection paper for extra credit events. double space, one page(five pages in total)
- discussion
- Performance Evaluation Assignment Much research has been conducted on the effectiveness of the evaluation process that many employers use. This is an especially interesting topic because, in many instances, an employee’s performance evaluation is linked
- business plan